News on immunohistochemistry and other tissue-based testing methods.
OncoDNA said that it will use next-generation sequencing and immunohistochemistry assays to analyze patient to identify potential biomarkers and molecular alterations.
Collaborators have created an atlas that compares available PD-L1 IHC assays and reveals areas of debate, including challenges encountered by clinicians.
Castle will use the proceeds to accelerate marketing and new product development related to its molecular prognostic tests for patients with underserved cancers.
The firm manufactures tissue culture-based personalized medicine assays that assesses signaling pathways to guide oncology diagnosis and treatment.
In separate deals, Poplar Healthcare will pay the federal government nearly $900,000, while Piedmont Pathology will pay $601,000.
